PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2013 | 20 | 1 |
Tytuł artykułu

Type III Polyglandular Autoimmune Syndromes in children with type 1 diabetes mellitus

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Introduction: Type III Polyglandular Autoimmune Syndrome (PAS III) is composed of autoimmune thyroid diseases associated with endocrinopathy other than adrenal insufficiency. This syndrome is associated with organ-specific and organ-nonspecific or systemic autoimmune diseases. The frequency of PAS syndromes in diabetic children is unknown. Objectives: The aim of the study was to evaluate the incidence of PAS III in children with diabetes mellitus type 1. Patients and methods: The study consisted of 461 patients with diabetes mellitus type 1(T1DM), who were 1-19 years of age. TSH, free thyroxin, TPO autoantibodies, and thyroglobulin autoantibodies were determined annually. Autoimmune Hashimoto’s thyroiditis was diagnosed in children with positive tests for TPO Ab and Tg Ab and thyroid parenchymal hypogenicity in the ultrasound investigation. Elevated TSI antibodies were used to diagnose Graves’ disease. Additionally, Anti-Endomysial Antibodies IgA class were determined every year as screening for celiac disease. During clinical control, other autoimmune diseases were diagnosed. Adrenal function was examined by the diurnal rhythm of cortisol. Results: PAS III was diagnosed in 14.5% children: PAS IIIA (T1DM and autoimmune thyroiditis) was recognized in 11.1 % and PAS III C (T1DM and other autoimmune disorders: celiac disease, and JIA, psoriasis and vitiligo) in 3.5% children. PAS IIIA was more prevalent in girls than in boys – 78.4% versus 21.6% (p<0.05). PAS III was observed between 1-5 years of life in 66.6% children; the frequency decreased in consecutive years and successively increased in the adolescence period to 22.7%. Conclusions: PAS III occurs in 14.5% of children with DM type1 and the incidence is positively correlated with patients’ age and female gender. Children with PAS III should be carefully monitored as a group at risk for the development of other autoimmune diseases.
Słowa kluczowe
Wydawca
-
Rocznik
Tom
20
Numer
1
Opis fizyczny
p.140-146,fig.,ref.
Twórcy
  • Department of Paediatric Endocrinology and Diabetology, Medical University, Lublin, Poland
  • Department of Paediatric Endocrinology and Diabetology, Medical University, Lublin, Poland
autor
  • Department of Paediatric Endocrinology and Diabetology, Medical University, Lublin, Poland
  • Department of Paediatric Endocrinology and Diabetology, Medical University, Lublin, Poland
autor
  • Department of Paediatric Endocrinology and Diabetology, Medical University, Lublin, Poland
Bibliografia
  • 1. Neufeld M, Blizzard RM. Polyglandular autoimmune disease. In: Pinchera A, Doniach D, Fenzi DF, Baschieri L, eds. Autoimmune aspectsof endocrine disorders. London, UK: Academic Press; 1980:357-65.
  • 2. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004; 350(20): 2068-79.
  • 3. Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?. Clin Exp Immunol. 2004;137(2): 225-33.
  • 4. Bahceci M, Tuzcu A, Pasa S, Ayyildiz O, Tuzcu S. Polyglandular autoimmune syndrome type III accompanied by common variableimmunodeficiency. Gynecol Endocrinol. 2004; 19(1): 47-50.
  • 5. Turkoglu Z, Kavala M, Kolcak O, Zindanci I, Can B. Autoimmune polyglandular syndrome-3C in a child. Dermatol Online J. 2010; 16(3): 8.
  • 6. Kahaly GJ. Polyglandular autoimmune syndromes. Eur J Endocrinol. 2009; 161(1): 11-20.
  • 7. Grzywa M. Cukrzyca typu 1 – istotny składnik zespołów poliendokrynopatii autoimmunologicznych Diabet Pol. 2005; 12: 271-274.
  • 8. Otto-Buczkowka E, Jarosz Chobot P. – Autimmunologiczne zespoły poliendokrynne Endokrynologia, Diabetologia i Choroby Przem Mat.Wieku Rozwojowego. 2000; 6(2): 117-119.
  • 9. Lorini R, Gastaldi R, Traggiai C, Perucchin PP. Hashimoto`s thyroiditis. Pediatric Endocrinol Rev. 2003; Suppl 2: 205-211
  • 10. Karagüzel G, Simşek S, Değer O, Okten A. Screening of diabetes, thyroid, and celiac diseases-related autoantibodies in a sample ofTurkish children with type 1 diabetes and their siblings. Diabetes ResClin Pract. 2008; 80(2): 238-43. Epub 2008 Jan 31.
  • 11. Kakleas K, Paschali E, Kefalas N, et al. Factors for thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Ups J MedSci. 2009; 114: 214-220.
  • 12. Karavanaki, K, Kakleas K, Paschali E, Kefalas N, Konstantopoulos I, Petrou V, Kanariou M, Karayianni C. Screening for AssociatedAutoimmunity in Children and Adolescents with Type 1 DiabetesMellitus (T1DM). Horm Res. 2009; 71: 201-206.
  • 13. Kordonouri O, Klinghammer A, Lang EB, Grüters-Kieslich A, Grabert M, Holl RW. Thyroid autoimmunity in children and adolescents withtype 1 diabetes: a multicenter survey. Diabetes Care. 2002; 25: 1346-1350.
  • 14. Piątkowska E, Szalecki M. Autoimmune thyroiditis in children and adolescents with type 1 diabetes. Ped End Diab Metab. 2011; 17(4):173-177.
  • 15. Szypowska A, Ramotowska A, Lipka M, Procner-Czaplińska M, Trippenbach-Dulska H. The prevalence of autoimmune thyroid diseaseand celiac disease in children and adolescents with newly recognizedtype 1 diabetes mellitus – individual results. Przegl Ped. 2010; 40(3):142-145.
  • 16. Górska A, Nazim J, Starzyk J. Ocena częstości występowania choroby Hashimoto oraz celiakii wśród dzieci i młodzieży ze świeżo rozpoznanącukrzycą typu 1 – badanie prospektywne. Endokrynol Ped. 2004; 3,S.3: 38.
  • 17. Kordonouri O, Hartmann R, Deiss D, Wilms M, Gruters-Kieslich A. Natural course of autoimmune thyroiditis in type 1 diabetes: associationwith gender, age, diabetes duration, and puberty. Arch Dis Child. 2005;90: 411-414.
  • 18. Mantovani RM, Mantovani LM, Dias VM. Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus prevalence andrisk factors. J Pediatr Endocrinol Metab. 2007; 20: 669-675.
  • 19. Kondrashova A, Viskari H, Haapala AM, Seiskari T, Kulmala P, Ilonen J, Knip M, Hyöty H. Serological evidence of thyroid autoimmunityamong schoolchildren in two different socioeconomic environments.J Clin Endocrinol Metab, 2008; 93: 729-734.
  • 20. Brix TH, Knudsen GP, Kristiansen M, Kyvik KO, Orstavik KH, Hegedüs L. High frequency of skewed X -chromosome inactivationin females with autoimmune thyroid disease: a possible explanation forthe female predisposition to thyroid autoimmunity. J Clin EndocrinolMetab. 2005; 90: 5949-5953.
  • 21. Barker JM. Clinical review: Type 1 diabetes -associated autoimmunity: natural history, genetic associations, and screening. J Clin EndocrinolMetab. 2006; 91: 1210-1217.
  • 22. Glastras SJ, Craig ME, Verge CF, Chan AK, Cusumano JM, Donaghue KC. The role of autoimmunity at diagnosis of type 1 diabetes inthe development of thyroid and celiac disease and microvascularcomplications. Diabetes Care. 2005; 28: 2170-2175.
  • 23. Czerniawska E, Szalecki M, Piątkowska E, Młynarski W, Bodalski J, Lewiński A. Występowanie przeciwciał przeciwtarczycowych (TPOi ATG) u dzieci ze świeżo rozpoznaną cukrzycą typu 1 leczonych wdwóch ośrodkach diabetologicznych: łódzkim i kieleckim. Med WiekuRozw. 2003; 2: 223-228.
  • 24. Szalecki M. Screening for thyroid disease in the paediatric insulin dependent diabetic population in Kielce Province. Horm Res. 1998;50: 147.
  • 25. Kalicka-Kasperczyk A, Dziatkowiak H, Nazim J, Pituch-Noworolska A, Kasperczyk K, Bartnik-Mikuta A, et al. Występowanie przeciwciałprzeciwko tyreoperoksydazie i chorób tarczycy u dzieci i młodzieżyz cukrzycą typu 1 w południowej Polsce. Przegl Lek. 2003; 60: 403-406.
  • 26. Kalicka-Kasperczyk A, Dziatkowiak H, Bartnik-Mikuta A, Pituch- Noworolska A, Kasperczyk K, Nazim J, et al. Występowanie przeciwciałprzeciw peroksydazie tarczycowej i chorób tarczycy u dzieci imłodzieży ze świeżo rozpoznaną cukrzycą typu I. Przegl Lek. 2002;59: 509-513.
  • 27. Kordonouri O, Hartmann R, Riebel T, Liesenkoetter KP. Early treatment with L -thyroxine in children and adolescents with type 1diabetes, positive thyroid antibodies, and thyroid gland enlargement.Pediatr Diabetes. 2007; 8: 180-184.
  • 28. ISPAD Clinical Practice Consensus Guidelines Compendium 2009. Pediatr Diabetes. 2009; 10(Suppl 12): 1-210.
  • 29. Grzeszczak W. Zalecenia Kliniczne Dotyczące Postępowania u Chorych na Cukrzycę, 2009. Opracowane przez Polskie TowarzystwoDiabetologiczne. Med Dypl. 2009; S2/09.
  • 30. Czech A, Cypryk K, Czupryniak L, Grzeszczak W, Gumprecht J, Idzior- Waluś B, et al. Zalecenia kliniczne dotyczące postępowania u chorychna cukrzycę Stanowisko Polskiego Towarzystwa Diabetologicznego.Diabetol Prakt. 2011; 12(Suppl A): A36–A392011.
  • 31. Villano MJ, Huber AK, Greenberg DA, et al. Autoimmune thyroiditis and diabetes: dissecting the joint genetic susceptibility in a large cohortof multiplex families. J Clin Endocrinol Metab. 2009; 94(4): 1458-66.
  • 32. Huber A, Menconi F, Corathers S, et al. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology tomechanisms. Endocr Rev. 2008; 29(6): 697-725.
  • 33. Fourati H, Mahfoudh N, Abida O, Kammoun A, Mnif F, Haddouk S, et al. HLA-DRB1/DQB1 susceptibility for autoimmune polyglandularsyndrome type II and III in south of Tunisia. Ann Endocrinol (Paris).2011; 72(3): 232-8.
  • 34. Dittmar M, Kahaly GJ. Genetics of the autoimmune polyglandular syndrome type 3 variant. Thyroid. 2010; 20(7): 737-43.
  • 35. Karges B, Muche R, Knerr I, Ertelt W, Wiesel T, Hub R, et al.Levothyroxine in euthyroid autoimmune thyroiditis and type 1diabetes: a randomized, controlled trial. J Clin Endocrinol Metab.2007; 92: 1647-1652.
  • 36. Padberg S, Heller K, Usadel KH, Schumm-Draeger PM. One-year prophylactic treatment of euthyroid Hashimoto’s thyroiditis patientswith levothyroxine: is there a benefit? Thyroid. 2001; 11: 249-255.
  • 37. Otoda T, Sakurai M, Ota T, Kurita S, Misu H, Shimizu A, et al. Two cases of type 1 diabetes mellitus accompanied by Graves’ disease. J JapanDiab Soc. 2008; 51(4): 323-327.
  • 38. Galli-Tsianopoulou A, Nousia-Arvanitakis S, Dracoulacos D. Autoantibodies predicting diabetes mellitus type I in celiac disease.Horm Res. 1999; 52: 119-124.
  • 39. Doolan A, Donaghue K, Fairchild JF. Use of HLA typing in diagnosing celiac disease in patients with type 1 diabetes. Diabetes Care. 2005;28: 806-809.
  • 40. Sumnik Z, Koluskova S, Cinek O. HLA -DQA180201 positivity predisposes to celiac disease in Czech diabetic children. Acta Paediatr.2007; 89: 1426-1430.
  • 41. Hill I, Fasano A, Schwartz R. The prevalence of celiac disease in at -risk groups of children in the United States. J Pediatr. 2000; 136: 86-90.
  • 42. Mäki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, et al. Prevalence of celiac disease among children inFinland. N Engl J Med. 2003; 348: 2517-2524.
  • 43. Hansen D, Bennedback FN, Hansen LK. High prevalence of celiac disease in Danish children with type 1 diabetes mellitus. Acta Peadiatr.2001; 90(11): 1217-1220.
  • 44. Ludvigsson IF, Ludvigson J, Ekbom A. Celiac disease and risk of subsequent type 1 diabetes: a general population cohort study ofchildren and adolescents. Diabetes Care. 2006; 29: 2483-2488.
  • 45. Li Voon Chong JS, Leong KS, Wallymahmed M. Is celiac disease more prevalent in young adult with coexisting type 1 diabetes mellitus andautoimmune thyroid disease compared with those with type 1 diabetesmellitus alone? Diabet Med. 2002; 19: 334-337.
  • 46. Picarelli A, Sabbatella L, Di Tola M, Vetrano S, Casale C, Porowska B, Gargiulo P. Anti-endomysial antibody of IgG1 isotype detectionstrongly increases the prevalence of celiac disease in patients affectedby type 1 diabetes mellitus. Clin Exp Immunol. 2005; 142: 11-15.
  • 47. Michałowicz-Wojcieszyńska E, Konieczny P, Załuska J. Występowanie celiakii u dzieci w województwach ostrołęckim i siedleckim. Przegl Ped. 1996; S.1/3: 67-74.
  • 48. Czerwionka-Szaflarska M, Swincow G, Szaflarska-Szczepanik A. Zachorowalność na glutenozależną chorobę trzewną u dzieciwojewództwa bydgoskiego w ostatnim dwudziestoleciu. Przegl Ped.1996; S.1/1: 45 -50.
  • 49. Domagała Z. Częstość występowania i obraz kliniczny choroby trzewnej u dzieci w województwie kieleckim w latach 1984 -1995.Rozprawa na stopień doktora nauk medycznych. Zabrze 1997.
  • 50. Arentz-Hansen A, Fleckenstein B, Moberg O. HLA DQ2 and DQ8 signatures of gluten T cell epitopes in celiac disease. Clin Invest. 2006;116: 2226-2232.
  • 51. Crone J, Rami B, Huber WD, Granditsch G, Schober E. Prevalence of celiac disease and follow up to EMA in children with type 1 diabetesmellitus. J Pediatr Gastroenterol Nutr. 2003; 37: 67-71.
  • 52. Sanchez-Albisua I, Wolf J, Neu A, Geiger H, Wäscher I, Stern M. Celiac disease in children with Type 1 diabetes mellitus: the effect of the gluten-free diet. Diabet Med. 2005; 22: 1079-1082.
  • 53. Myśliwiec M, Balcarska A, Stopiński J. Prognostic factors of celiac disease occurrence in type 1 diabetes mellitus children. EndokrDiabetol Chor Przem Mati Wieku Rozw. 2006; 12: 281-285.
  • 54. Górska A, Nazim J, Starzyk J. Ocena częstości występowania choroby Hashimoto oraz celiakii wśród dzieci i młodzieży ze świeżo rozpoznanącukrzycą typu 1 – badanie prospektywne. Endokrynol Ped. 2004; 3,S.3: 38.
  • 55. Szalecki M, Piątkowska E, Nawrotek J. Badania przesiewowe w kierunku celiakii u dzieci i młodzieży z cukrzycą typu 1. Nowa Pediatria 2003;33: 35.
  • 56. Giletti PM, Giletti HR, Israel DM. High prevalence of celiac disease in patients with type 1 diabetes detected by antibodies to endomysiumand tissue transglutaminase. Can J Gastroenterol. 2003; 15: 297-301.
  • 57. Mathieu S, Stassen A, Paquot N, Scheen AJ. Type 1 diabetes and celiac disease. Rev Med Liege. 2006; 61: 637-642.
  • 58. Calvo G, Rica J, Vittoria JC. Conserved extend haplotypes discriminate HLA -DR3 -homozygous Basque patients with type 1 diabetes mellitusand celiac disease. Genes Immun. 2006; 7: 550-554.
  • 59. Młynarski W. Podłoże genetyczne współwystępowania chorób autoimmunologicznych z cukrzycą typu 1. [In:] Cukrzyca typu 1, ed.E. Otto-Buczkowska. Cornetis, Wrocław 2006 p. 149-156.
  • 60. Hansed D, Brock-Jacobsen D, Lund E. Clinical benefit of gluten-free diet in type 1 diabetic children with screening-detected celiac disease:a population-based screening study with 2 years’ follow-up. DiabetesCare. 2006; 29: 2452-2456.
  • 61. Acerini CL, Ahmed MI, Ross KM. Coeliac disease in children and adolescents with IDDM: clinical characteristic and response to gluten--free diet. Diabet Med. 1998; 15: 38-44.
  • 62. Fuchtenbush M, Ziegler AG, Hummel M. Elimination of dietary gluten and development of type 1 diabetes high risk subjects. Rev DiabetStudy. 2004; 1: 39-41.
  • 63. Pohjankoski H, Kautiainen H, Korppi M, Savolainen A. Simultaneous juvenile idiopathic arthritis and diabetes mellitus type 1- a FinnishNationwide study. J Rheumatol. 2012; 39(2): 377-381.
  • 64. Rudolf MC, Genel M, Tamborlane WV Jr, Dwyer JM. Juvenile rheumatoid arthritis in children with diabetes mellitus. J Pediatr.1981; 99(4): 519-524.
  • 65. Nolfi-Donegan D, Viswanathan A, Wood R, et al. Case report of a child with recently diagnosed diabetes mellitus type 1 and subsequentsystemic Arthritis 2012 The Internet Journal of Pediatrics andNeonatology ISSN: 1528-8374.9 (access: 10.08.2012).
  • 66. Tack CJ, Kleijwegt FS, Van Riel PL, Roep BO. Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for activerheumatoid arthritis. Diabetologia 2009; 52: 1442-1444.
  • 67. Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. ArthritisRheum. 2000; 43: 2606-2608.
Uwagi
rekord w opracowaniu
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.agro-4c603d04-ebea-4539-9e16-88c8268644cd
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.